TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03525015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A decision aid booklet about cataract surgery choice
Description: Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: An usual booklet about cataract and cataract surgery
Description: Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
Study: NCT04211701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage
Description: Connective tissue massage (CTM) will be applied to the lumbo-sacral region, lower thoracic, scapular and interscapular regions. Three to five pulling will be applied during massage. The treatment will be administered for four weeks, five days a week.
Study: NCT02204488

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trapeziectomy
Description: Trapeziectomy
Study: NCT04135014

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and Dexmedetomidine
Description: oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
Study: NCT04211701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: Classic massage (CM) will be applied to the lower back and upper back while the patient is lying in the prone position. Three stroking will be applied during massage.The treatment will be administered for four weeks, five days a week.
Study: NCT03553407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser - Pulse
Description: The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser - continuous
Description: The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level Laser - placebo
Description: placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
Study: NCT01142310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00789893

Intervention type: DEVICE
Intervention: Vaginal Dilator
Description: Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis \& assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st \& 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, \& the 2nd will be one month ± 2 weeks from last day of radiation.
Study: NCT02730572

Intervention type: DRUG
Intervention: Concerta
Description: This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.

Intervention type: DRUG
Intervention: Concerta
Description: This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.

Intervention type: DRUG
Intervention: Concerta AG formulation
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.

Intervention type: DRUG
Intervention: Concerta EG formulation
Description: This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
Study: NCT01770483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitazoxanide
Description: nitazoxanide 500mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional interferon alfa
Description: Inj interferon 3 Million International Units thrice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional interferon alfa
Description: Inj interferon 3 Million International Units thrice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: ribazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribazole
Study: NCT03987061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOTIV BVS
Description: MOTIVS BVS in below-the-knee artery disease
Study: NCT01540708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SERETIDE Rotacaps
Description: The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERETIDE Diskus
Description: The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
Study: NCT02479256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
Study: NCT03731065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose-maltodextrin hydrogel
Description: Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-maltodextrin
Description: Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
Study: NCT04129138

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT01406509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml/dose for a person
Description: group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml/dose for a person
Description: group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
Study: NCT03432819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siempre Seguiré
Description: A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
Study: NCT01636050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squat exercise training
Description: Intervention may include squat exercise for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squat exercise training
Description: Intervention may include squat exercise for 8 weeks
Study: NCT03812224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erenumab
Description: Administered by subcutaneous injection once a month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection once a month
Study: NCT02825745

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Betashot
Description: Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
Study: NCT01344213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Study: NCT02404428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard broccoli soup
Description: 300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beneforte extra broccoli soup
Description: 300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
Study: NCT02706197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyChip
Description: The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OxyChip
Description: The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
Study: NCT01551524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mPEG-r-crisantaspase
Description: IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
Study: NCT01610986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose-fructose
Description: 0.8 g/h glucose and 0.5 g/h fructose during training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water
Description: Only water intake during training
Study: NCT05004948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The first group conducted a resistance exercise program (REP, 50-60% of 1RM, for 40-50 min) combined with metformin, the second group conducted an aerobic exercise program (AEP, 50-70% maxHR, for 40-50 min) combined with metformin, and the third group received only metformin without exercise intervention (Met group). The study program was conducted thrice weekly for consecutive twelve weeks.
Study: NCT05390658

Intervention type: OTHER
Intervention: Not application
Description: Not application

Intervention type: OTHER
Intervention: Not application
Description: Not application
Study: NCT03127423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Description: This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic surgical ablation
Description: This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
Study: NCT03964792

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DREPAGLOBE drug product
Description: Each patient will receive a single IV infusion of DREPAGLOBE drug product
Study: NCT03035682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Media Group
Description: The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Group
Description: The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
Study: NCT03926988

Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retriever
Description: mechanical neurothrombectomy
Study: NCT03350555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additioned Endoscopy
Description: To evaluate the use of additioned endoscopy in ERCP treatment.
Study: NCT03090672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Normal Saline IV delivery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Stromal Vascular Fraction
Description: tSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Stromal Vascular Fraction
Description: tSVF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction
Description: cSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction
Description: cSVF
Study: NCT04516772

Intervention type: DEVICE
Group type: OTHER
Intervention: Visian TICL
Description: The Visian TICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.
Study: NCT02135978

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder home exercise program
Description: Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder home exercise program
Description: Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
Study: NCT02870088

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Sitting
Description: After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
Study: NCT01593137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide + metformin
Description: Liraglutide 1.8 mg/day + metformin \>1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment.
Study: NCT02870088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking Sitting
Description: After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
Study: NCT01593137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride + metformin
Description: Glimepiride 4 mg/day + metformin \>1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment.
Study: NCT01266317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Description: Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
Study: NCT03441698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture (A)
Description: A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture (B)
Description: B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
Study: NCT03034863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Actions for Families to Encourage Recovery
Description: A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Safety Planning Intervention
Description: The comparison condition will be an assessment-only enhanced treatment-as-usual intervention called the Individual Safety Planning Intervention (I-SPI).